CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Crispr Therapeutics maintains leadership in gene editing, with shares up 75% YTD and renewed investor interest after positive CTX-310 data. CRSP's in-vivo therapy shows promising early results, ...